Over the past twelve months, LCI has reported earnings growth of -112.7%, putting it ahead of just 14.82% of US stocks in our set.
Revenue growth over the past 12 months for Lannett Co Inc comes in at -21.78%, a number that bests just 9.05% of the US stocks we're tracking.
Lannett Co Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 34.17%, greater than the shareholder yield of 92.35% of stocks in our set.
Stocks that are quantitatively similar to LCI, based on their financial statements, market capitalization, and price volatility, are TLGT, ENT, HL, FCEL, and TEAR.
Lannett Company develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. The company was founded in 1942 and is based in Philadelphia, Pennsylvania.
LCI Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for LCI, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Lannett Co Inc ranked in the 37th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Lannett Co Inc ended up being:
Interest coverage, a measure of earnings relative to interest payments, is 0.46 -- which is good for besting merely 24.51% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
28% of the company's capital comes from equity, which is greater than only 13.42% of stocks in our cash flow based forecasting set.
Lannett Co Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Lannett Co Inc? See AMED, HBIO, HAE, BDX, and IQV.
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
Lannett Company, Inc. (NYSE: LCI) today said that representatives from the company spoke with and received guidance from the U.S. Food and Drug Administration (FDA) on the clinical advancement program of its biosimilar insulin glargine partnered product candidate. Insulin glargine is a long-acting insulin used to treat adults with Type 2 diabetes, as well as adults and pediatric patients with Type 1 diabetes, for the control of high blood sugar. Total U.S. sales of the glargine related products, according to IQVIA, were approximately $9.5 billion for the 12 months ending April 2020, although actual biosimilar market values are expected to be lower.